This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2013 by Schroppel, Bernd, M.D..
Recruitment status was:  Recruiting
Alexion Pharmaceuticals
Information provided by (Responsible Party):
Schroppel, Bernd, M.D. Identifier:
First received: July 25, 2011
Last updated: January 25, 2013
Last verified: January 2013
The purpose of this study is to determine if Eculizumab is safe and effective in the prevention of delayed graft function following deceased donor kidney transplantation.

Condition Intervention Phase
Delayed Function of Renal Transplant Drug: Eculizumab Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Pilot Study of the Clinical Activity of Eculizumab for Prevention of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Resource links provided by NLM:

Further study details as provided by Schroppel, Bernd, M.D.:

Primary Outcome Measures:
  • Composite of Delayed Graft Function and Slow Graft Function [ Time Frame: Up to 6 months ]

    Delayed Graft Function defined as follows:

    1. A need for at least one dialysis treatment during the first 7 days after transplantation (not including a single session for hyperkalemia or hypervolemia in the first 48 hours)
    2. A less than or equal to 50% reduction in serum creatinine in the first 24 hours post-transplantation
    3. A serum creatinine reduction ratio < 30% at 48 hours post-transplantation

    Slow Graft Function Defined as Follows:

    A functioning graft at Day 5 Post-transplantation with a serum creatinine > 3 mg/dL and no need for dialysis

Estimated Enrollment: 20
Study Start Date: August 2011
Estimated Study Completion Date: February 2014
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Eculizumab Drug: Eculizumab
1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
Other Name: Soliris
Placebo Comparator: 0.9% Sodium Chloride Drug: Placebo
240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Other Name: 0.9% Sodium Chloride

Detailed Description:
Based on experimental data and supportive observations in humans associating complement gene upregulation with ischemic reperfusion injury, it is hypothesized that C5 cleavage is a key step in the pathogenesis of ischemic reperfusion injury following transplantation. It is further hypothesized that eculizumab, an antibody that blocks C5 cleavage in humans will be an effective prophylactic agent to prevent ischemic reperfusion injury in high risk recipients. To test this hypothesis, this study is a pilot prospective, randomized study to test the efficacy of eculizumab vs. placebo given once at the time of transplantation in preventing delayed graft function in first adult recipients of deceased donor kidneys.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Weight > 40 kg
  • Male or Female
  • Recipients of first deceased donor kidneys
  • Able to provide written informed consent
  • Transplant candidate as per site specific guidelines
  • Dialysis dependent renal failure (initiated more than 2 months prior to transplant)
  • Novartis Delayed Graft Function Score 3-8
  • Extended criteria donor with brain death, or standard criteria donor with cold ischemic time < 24 hours

Exclusion Criteria:

  • Planned to receive multi-organ transplant
  • Kidneys from donors < 6 years of age
  • Dual kidney transplant (from same donor, including en bloc)
  • Living donor kidney
  • Highly sensitized recipients (PRA > 50%)
  • Previous transplant
  • Participation in another investigational trial
  • Recipient BMI > 40
  • ABO incompatible
  • DCD Donor
  • Preemptive kidney transplant
  • Recipients with DGF scores < 3 or > 8
  • Women who are pregnant or breast feeding
  • Women of child bearing potential who are unable or unwilling to use a medically acceptable form of contraception
  • Patients infected with HIV, HCV or HBV
  • Active bacterial or other infection which is clinically significant in the opinion of the investigator
  • Patients with history of splenectomy
  • Patients with history of meningococcal disease
  • Patients with known or suspected hereditary complement deficiency
  • Patients with history of cancer (other than non-melanoma skin cancers) within the last 5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01403389

Contact: Bernd Schroppel, MD 212-659-8086
Contact: Brandy Haydel, CCRC 212-241-0255

United States, New York
Mount Sinai Recanati/Miller Transplantation Institute Recruiting
New York, New York, United States, 10029
Contact: Bernd Schroppel, MD    212-659-8086   
Contact: Brandy Haydel, CCRC    212-241-0255   
Principal Investigator: Bernd Schroppel, MD         
Sub-Investigator: Peter Heeger, MD         
Sponsors and Collaborators
Schroppel, Bernd, M.D.
Alexion Pharmaceuticals
Principal Investigator: Bernd Schroppel, MD Icahn School of Medicine at Mount Sinai
  More Information

Responsible Party: Schroppel, Bernd, M.D. Identifier: NCT01403389     History of Changes
Other Study ID Numbers: HSM 10-1600
Study First Received: July 25, 2011
Last Updated: January 25, 2013

Keywords provided by Schroppel, Bernd, M.D.:
Kidney Transplant
Delayed Graft Function

Additional relevant MeSH terms:
Delayed Graft Function
Pathologic Processes processed this record on August 16, 2017